Although previous population-based studies have shown worse clinical outcomes for minority patients with DLBCL compared with white patients, this study reported no differences in PFS and OS were seen between the 2 groups.
In phase 2 analyses, patients receiving polatuzumab vedotin experienced improved overall and progression-free survival compared with patients in the control arm.
Researchers noted that bridging while awaiting CAR-T manufacturing may not be appropriate for all patients, and in some cases, bridging was associated with worse PFS and OS.
Despite improved survival in patients with B cell malignancies who are treated with PI3K inhibitors, researchers found incidences of pneumonitis, infections, and sepsis are higher in these patients.
Researchers found that CIRS scores are prognostic for overall and progression-free survival in patients with R/R DLBCL being evaluated for CAR-T therapy.
Cancer, particularly non-Hodgkin lymphoma, remains a leading cause of death in patients with HIV who are being treated with antiretroviral therapy.
Using culture analysis and sequencing analysis, researchers found a correlation between CTCL and the presence of S aureus in patients’ skin flora.
A prospective study followed more than 3000 patients with lymphoma to determine the potential risk for developing anthracycline-induced CVD.
Researchers sought to determine the opportunity costs for patients and caregivers in the inpatient vs outpatient settings for patients undergoing ASCT.
This study used atomic absorption spectrometry to evaluate the levels of trace metals in specimens of patients with lymphoma compared with healthy controls.
